Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioHarvest Sciences Inc.

Market Cap 74.35M 64.14M 58.97M 55.51M 104M 7.02B 105M 699M 272M 3.44B 279M 273M 11.91B P/E 2026 *
-8.05x
P/E 2027 * -19.9x
Enterprise Value 74.35M 64.14M 58.97M 55.51M 104M 7.02B 105M 699M 272M 3.44B 279M 273M 11.91B EV / Sales 2026 *
1.73x
EV / Sales 2027 * 1.26x
Free-Float
85.23%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 68 29/04/2026
Director of Finance/CFO - 28/10/2024
Chief Operating Officer 65 19/04/2023
Director TitleAgeSince
Chairman 68 27/09/2018
Director/Board Member 67 27/09/2018
Director/Board Member 84 07/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.06%-2.94% - - 75.03M
-1.01%-2.45%-11.95%-8.34% 13.04B
-1.76%-2.56%-33.85%-57.02% 4.94B
-1.36%-5.62%-9.78%-3.57% 4.56B
-1.31%-1.28%+14.19%-16.43% 3.83B
-1.06%-3.42%+4.33%-44.05% 3.73B
-1.24%-3.14%-5.30%-10.10% 3.62B
-0.77%-1.61%-10.02%-3.42% 3.14B
-1.35%+4.69%-5.58%-25.94% 2.43B
-1.06%-7.05%-12.94%+32.11% 1.72B
Average -0.49%-0.80%-7.88%-15.20% 4.56B
Weighted average by Cap. -1.18%-1.69%-9.36%-16.81%

Financials

2026 *2027 *
Net sales 42.89M 37M 34.02M 32.02M 60.17M 4.05B 60.67M 403M 157M 1.99B 161M 158M 6.87B 58.96M 50.86M 46.76M 44.01M 82.71M 5.56B 83.4M 554M 216M 2.73B 221M 217M 9.45B
Net income -9.27M -7.99M -7.35M -6.92M -13M -874M -13.11M -87.09M -33.91M -429M -34.78M -34.03M -1.48B -3.77M -3.26M -2.99M -2.82M -5.29M -356M -5.34M -35.47M -13.81M -175M -14.16M -13.86M -605M
Net Debt - -
Logo BioHarvest Sciences Inc.
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.280USD
Average target price
12.75USD
Spread / Average Target
+288.72%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!